Overview and Scope
Autologous cell therapy refers to a type of cell therapy where a patient’s own cells are collected, processed, and then reintroduced into their own body for therapeutic purposes. It is often used in regenerative medicine to repair, replace, or restore damaged tissues or organs.
Sizing and Forecast
The autologous cell therapy market size has grown rapidly in recent years. It will grow from $8.58 billion in 2023 to $10.22 billion in 2024 at a compound annual growth rate (CAGR) of 19.2%. The growth in the historic period can be attributed to advancements in regenerative medicine, increased prevalence of chronic diseases, enhanced understanding of cellular biology, patient preference for personalized medicine, clinical success and positive outcomes..
The autologous cell therapy market size is expected to see rapid growth in the next few years. It will grow to $19.53 billion in 2028 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to continued growth in regenerative medicine, expanding applications across medical specialties, advancements in cell culture techniques, increasing investment and research initiatives, regulatory support and standardization.. Major trends in the forecast period include development of automated manufacturing technologies, integration of biomarkers in treatment strategies, emergence of point-of-care cell processing, expansion beyond hematopoietic stem cells, collaborations and partnerships in the industry..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report
Segmentation & Regional Insights
The autologous cell therapy market covered in this report is segmented –
1) By Therapy: Autologous Stem Cell Therapy, Autologous Cellular Immunotherapies
2) By Source: Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Chondrocytes, Other Sources
3) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Other Applications
4) By End User: Hospitals And Clinics, Ambulatory Centers, Academics And Research, Other End-Users
North America was the largest region in the autologous cell therapy market in 2023. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10771&type=smp
Major Driver Impacting Market Growth
The high prevalence of chronic diseases is expected to drive the growth of autologous cell therapy. Chronic disease is a condition or illness that lasts more than a year and requires ongoing medical treatment. Autologous cell therapy offers a promising approach for treating and managing these conditions that use an individual’s cells, which are cultivated and enlarged outside the body before being reintroduced into the donor. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older who have at least 1 chronic condition would increase to 142.66 million by 2050. Thus, the high prevalence of chronic diseases is driving the growth of the autologous cell therapy market.
Key Industry Players
Major companies operating in the autologous cell therapy market report are Bristol-Myers Squibb Company, Novartis AG, Vericel Corporation, Holostem Terapie Avanzate S.r.l., Pharmicell Co. Ltd., Opexa Therapeutics Inc., Tego Science AB, Brainstorm Cell Therapeutics Inc., Caladrius Biosciences Inc., Lineage Cell Therapeutics Inc., Castle Creek Biosciences Inc., Gilead Sciences Inc., Johnson & Johnson, CORESTEM Inc., Dendreon Pharmaceuticals LLC, Medipost Co. Ltd., PharmaJet Inc., Bioject Medical Technologies Inc., Medical International Technology Inc., INJEX Pharma AG, Lonza Group Ltd., Corning Incorporated, Takeda Pharmaceutical Company Limited, CSL Limited, AstraZeneca PLC, Moderna Inc., Sinovac Biotech Ltd., Valneva SE, Bavarian Nordic A/S, Dynavax Technologies Corporation
The autologous cell therapy market report table of contents includes:
1. Executive Summary
2. Autologous Cell Therapy Market Characteristics
3. Autologous Cell Therapy Market Trends And Strategies
4. Autologous Cell Therapy Market – Macro Economic Scenario
5. Global Autologous Cell Therapy Market Size and Growth
.
.
.
31. Global Autologous Cell Therapy Market Competitive Benchmarking
32. Global Autologous Cell Therapy Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Autologous Cell Therapy Market
34. Autologous Cell Therapy Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The digital transaction management market size is expected to see exponential growth in the next…
The data center solutions market size is expected to see rapid growth in the next…
The communication test and measurement market size is expected to see strong growth in the…
The carbon accounting software market size is expected to see exponential growth in the next…
The autonomous train components market size is expected to see rapid growth in the next…
The corporate e-learning global market report 2024 from The Business Research Company provides comprehensive market…